share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  07/29 16:11
Moomoo AI 已提取核心訊息
TC BioPharm (Holdings) plc successfully conducted its 2024 Annual General Meeting (AGM) on July 24, 2024, with all proposed resolutions passed. The AGM saw the approval of the company's annual report and audited financial statements for the year ended December 31, 2023. Shareholders also approved the Directors' Remuneration Report for the same period. Marcum LLP was ratified as the U.S. independent registered public accounting firm for the upcoming year, while Ecovis was re-appointed as the U.K. statutory auditor until the next AGM. Additionally, the Audit Committee was authorized to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2024. A provision to adjourn the AGM to a later date if necessary was also approved. The full text of each resolution was included in the Notice of Annual General Meeting distributed to shareholders on July 1, 2024, and filed with the U.S. Securities and Exchange Commission.
TC BioPharm (Holdings) plc successfully conducted its 2024 Annual General Meeting (AGM) on July 24, 2024, with all proposed resolutions passed. The AGM saw the approval of the company's annual report and audited financial statements for the year ended December 31, 2023. Shareholders also approved the Directors' Remuneration Report for the same period. Marcum LLP was ratified as the U.S. independent registered public accounting firm for the upcoming year, while Ecovis was re-appointed as the U.K. statutory auditor until the next AGM. Additionally, the Audit Committee was authorized to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2024. A provision to adjourn the AGM to a later date if necessary was also approved. The full text of each resolution was included in the Notice of Annual General Meeting distributed to shareholders on July 1, 2024, and filed with the U.S. Securities and Exchange Commission.
TC BioPharm（控股）plc於2024年7月24日成功舉行了2024年度股東大會（AGM），所有提議的決議都通過了。大會批准了公司2023年12月31日結束的年度報告和核數師覈准的財務報表。股東還批准了同期董事報酬報告。Marcum LLP被授權擔任未來一年的獨立註冊公共會計師事務所，在Ecovis則繼續擔任英國的法定核數師，直至下一屆股東大會。此外，審計委員會被授權判斷英國法定核數師2024年12月31日結束時的報酬。還批准根據需要將股東大會推遲到以後的日期。每個決議的全文均包含在於2024年7月1日發給股東並已提交給美國證券交易委員會的年度股東大會通知中。
TC BioPharm（控股）plc於2024年7月24日成功舉行了2024年度股東大會（AGM），所有提議的決議都通過了。大會批准了公司2023年12月31日結束的年度報告和核數師覈准的財務報表。股東還批准了同期董事報酬報告。Marcum LLP被授權擔任未來一年的獨立註冊公共會計師事務所，在Ecovis則繼續擔任英國的法定核數師，直至下一屆股東大會。此外，審計委員會被授權判斷英國法定核數師2024年12月31日結束時的報酬。還批准根據需要將股東大會推遲到以後的日期。每個決議的全文均包含在於2024年7月1日發給股東並已提交給美國證券交易委員會的年度股東大會通知中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息